Get screened based on your personal pancreatic cancer risk

Pancreatic cancer is often detected late because we don’t have routine screening for all adults. But, if you are identified as at-increased risk, screening options exist.

Understand your risk of developing pancreatic cancer.

Have a more informed discussion with your doctor about the options that exist for you.

Available through your healthcare provider.

 

Grandparents and firstborn grandson

Screening options exist for adults at high risk of pancreatic cancer. 

 

Do you know your risk? 

 

With geneType, you can get a better understanding of your risk.

Key features of a geneType report

● Understand your risk of pancreatic cancer

● A lifetime risk score and a 10-year risk score

● Discussion points around screening recommendations from the NCCN and USPSTF

pan-usa
Multi Test risk reduction plan with Doctor

Personalized risk score. Personalized health plan.

Would you benefit from pancreatic cancer screening?

GeneType can help you have a joint-decision-making discussion with your HCP.

Is geneType right for you?

  • Adults
  • Age 30-85 years
  • No known hereditary gene mutation e.g.  BRCA2

Uniquely powered to assess your risk

Get a clearer picture of your risk.

Make screening decisions that fit your needs.

Know your risk of pancreatic cancer, so you can take action.

Know your risk of pancreatic cancer so you can take action

Speak to your healthcare provider today about geneType.

To order online through our patient portal, follow these four simple steps to be connected with a third-party telehealth provider.

Step 1

Register for your geneType test using our portal.

Depending on the test, you may require access to your medical records (ex. lipid panel or breast density results). 

Payment will be collected at time of registration.

Step 2

Your clinical information will be reviewed by our 3rd party telehealth partner, DNA Visit.

If you qualify for testing, a kit will be shipped to your address on file.

If you do not qualify for testing, you will receive a refund.

Step 3

Complete saliva sample collection as instructed and return in pre-paid envelope.

Do not eat, drink, smoke, vape or chew gum within 30 minutes of collection. 

Step 4

When your results are ready, you will have the chance to speak with your DNA Visit healthcare provider.

All at-risk patients will be required to speak with the provider prior to results-release.

Order Now

Have questions? We have answers.

If your question is not shown here, please contact us directly.

Will insurance cover this test?

No. At this time geneType is a self-pay test. However, you may use FSA/HSA to pay for the test.

Can I order this test if I am a known carrier for a hereditary cancer syndrome (ie. BRCA1 or BRCA2)?

This test is not applicable to adults who have personal history of pancreatic cancer or who have already been shown to have a cancer mutation, for example in the BRCA1 or BRCA2 gene, or a diagnosis of a genetic syndrome that may be associated with an elevated risk of pancreatic cancer. 

Does this test incorporate all potential risk factors for pancreatic cancer?

Cancer is a multifactorial disease and there are many different risk factors. Of these, geneType integrates the most predictive risk factors into the model. Future models may include additional risk factors as the scientific community’s understanding of pancreatic cancer continues to evolve.

Multitest V3 2024

*Patient eligibility dependent on personal medical history, age and sex

Interested in ordering more than one disease? Order geneType Multi-Test.

See individual disease pages for more information about each test.

The Multi-Risk suite of tests is for adults 40-85 years of age. At maximum, a woman would be eligible for 8 diseases in the panel; a man would be eligible for 7. Starting at age 30, a patient may qualify for geneType's cancer risk assessments only.

What’s happening?

References
  1. Aslanian HR, Lee JH, Canto MI. AGA Clinical Practice Update on Pancreas Cancer Screening in High-Risk Individuals: Expert Review. Gastroenterology. 2020;159(1):358-362. doi:10.1053/j.gastro.2020.03.088
  2. Dite GS, Spaeth E, Wong CK, Murphy NM, Allman R. Predicting 10-year risk of pancreatic cancer using a combined genetic and clinical model,
    Gastro Hep Advances, online 2023. https://doi.org/10.1016/j.gastha.2023.05.008

Accredited For Compliance With NPAAC Standards And ISO 15189

CLIA Number 99D2023356

Thanks for your Order!

img OK